Open Access Open Access  Restricted Access Subscription or Fee Access

Evaluation of functional outcome measured by modified Rankin scale in rtPA treated patients with acute ischemic stroke

B Georgievski-Brkic, M Savic, D Nikolic, L Nikcevic, M Vukicevic, D Kozic


Aim of our study was to assess functional outcome measured by modified Rankin scale (mRS) in patients that were treated with thrombolytic therapy-recombinant tissue plasminogen activator (rtPA) after acute ischemic stroke. The study included 100 participants that were treated after acute ischemic stroke. Analyzed parameters included: gender; age groups: age 54 and below (Groupup to-54), 55-64 (Group55-64), 65-74 (Group65-74), and 75 and above (Group75-up); cerebral blood flow (CBF) and cerebral blood volume (CBV). Considering time of rtPA administration, we analyzed 3 groups: between 1-2 hours from stroke onset (Time1-2h), 2-3 hours (Time2-3h) and 3-4.5 hours (Time3h-up). NIHSS scores were analyzed: NIHSS 1-at admission and NIHSS 2-at discharge from hospital; and mRS values: RANKIN 1-at admission and RANKIN 2-at discharge from hospital. There is significant reduction in NIHSS and mRS scores between two measurements for all groups of evaluated parameters. CBF, CBV and NIHSS values at admission significantly correlated with mRS scores at admission (p<0.01), as well as with mRS scores at discharge except for CBF where statistical significance was (p=0.019). Significantly lower values of NIHSS at admission (p<0.01), CBF values (p<0.01) and CBV values (p<0.01) are noticed in the group with mRS≤2. Early induction of rtPA treatment in patients with acute ischemic stroke within first 4.5 hours significantly increases positive treatment outcome in both genders and for all evaluated age groups. Favorable outcome (mRS≤2) at the time of discharge from hospital is significantly associated with lower NIHSS values at admission.


acute ischemic stroke; thrombolysis; age; NIHSS; modified Rankin scale

Full Text:



Arkuszewski M., Swiat M., Opala G. Perfusion computed tomography in prediction of functional outcome in patients with acute ischaemic stroke. Nucl. Med. Rev. Cent. East. Eur., 12: 89-94, 2009.

Balu S. Differences in psychometric properties, cut-off scores, and outcomes between the Barthel Index and Modified Rankin Scale in pharmacotherapy-based stroke trials: systematic literature review. Curr. Med. Res. Opin., 25: 1329-1341, 2009.

Banks J.L. and Marotta C.A. Outcomes validity and reliability of the modified Rankin scale: implications for stroke clinical trials: a literature review and synthesis. Stroke, 38: 1091-1086, 2007.

Clark W.M., Wissman S., Albers G.W., Jhamandas J.H., Madden K.P., Hamilton S. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA, 282: 2019-2026, 1999.

Derex L., Nighoghossian N., Hermier M., Adeleine P., Berthezene Y., Philippeau F, Honnorat J., Froment J.C., Trouillas P. Influence of pretreatment MRI parameters on clinical outcome, recanalization and infarct size in 49 stroke patients treated by intravenous tissue plasminogen activator. J. Neurol. Sci., 225: 225:3-9, 2004.

Hacke W., Kaste M., Bluhmki E., Brozman M., Dávalos A., Guidetti D., Larrue V., Lees K.R., Medeghri Z., Machnig T., Schneider D., von Kummer R., Wahlgren N., Toni D; ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N. Engl. J. Med., 359: 1317-1329, 2008.

Huang P., Khor G.T., Chen C.H., Lin R.T., Liu C.K. Eligibility and rate of treatment for recombinant tissue plasminogen activator in acute ischemic stroke using different criteria. Acad. Emerg. Med., 18: 273-278, 2011.

Huybrechts K.F. and Caro J.J. The Barthel Index and modified Rankin Scale as prognostic tools for long-term outcomes after stroke: a qualitative review of the literature. Curr. Med. Res. Opin., 23: 1627-1636, 2007.

Kanekar S., Zacharia T., Roller R. Imaging of Stroke: Part 2, Pathophysiology at the molecular and cellular levels and corresponding imaging changes. AJR. Am. J. Roentgenol., 198: 63–74, 2012.

Mikulik R. and Wahlgren N. Treatment of acute stroke: an update. J. Intern. Med., 278: 145-165, 2015.

Molina CA, Alexandrov AV, Demchuk AM, Saqqur M, Uchino K, Alvarez-Sabín J; CLOTBUST Investigators. Improving the predictive accuracy of recanalization on stroke outcome in patients treated with tissue plasminogen activator. Stroke, 35: 151-156, 2004.

National Institute of Health, National Institute of Neurological Disorders and Stroke. Stroke Scale.

Quinn T.J., Dawson J., Walters M.R., Lees K.R. Exploring the reliability of the modified rankin scale. Stroke, 40: 762-766, 2009a.

Quinn T.J., Dawson J., Walters M.R., Lees K.R. Reliability of the modified Rankin Scale: a systematic review. Stroke, 40: 3393-3395, 2009b.

Radosavljevic N., Lazovic M., Nikolic D., Petronic I., Radosavljevic Z., Jeremic A. Influence of selective comorbidity predictors on functional recovery after hip fracture in an older population. Biomed. Pap., 156: 365-370, 2012.

Tosta E.D., Rebello L.C., Almeida S.S., Neiva M.S. Treatment of ischemic stroke with r-tPA: implementation challenges in a tertiary hospital in Brazil. Arq. Neuropsiquiatr., 72: 368-372, 2014.

Wardlaw J.M., Murray V., Berge E., del Zoppo G., Sandercock P., Lindley R.L., Cohen G. Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis. Lancet, 379: 2364-2372, 2012.

Wei X.E., Zhao Y.W., Lu J., Li M.H., Li W.B., Zhou Y.J., Li Y.H. Timing of recanalization and outcome in ischemic-stroke patients treated with recombinant tissue plasminogen activator. Acta Radiol., 56: 1119-1126, 2015.

Wilson J.T., Hareendran A., Hendry A., Potter J., Bone I., Muir K.W. Reliability of the modified Rankin Scale across multiple raters: benefits of a structured interview. Stroke, 36: 777-781, 2005.

Zhao H., Collier J.M., Quah D.M., Purvis T., Bernhardt J. The modified Rankin Scale in acute stroke has good inter-rater-reliability but questionable validity. Cerebrovasc. Dis., 29: 188-193, 2010.



  • There are currently no refbacks.